Alembic Pharmaceuticals secures US FDA approval for Ketorolac Tromethamine injectable as generic to Roche’s Toradol

Alembic Pharmaceuticals Limited has announced that it has received final approval from the United States Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) covering Ketorolac Tromethamine Injection USP in strengths of 15 mg/mL, 30 mg/mL, and 60 mg/2 mL (30 mg/mL) single-dose vials. The clearance allows the Indian pharmaceutical manufacturer to market the product as a generic equivalent to Roche’s Toradol Injection in the US market.

The non-steroidal anti-inflammatory drug (NSAID) is indicated for the short-term management of moderately severe acute pain in adults, typically for up to five days. Alembic Pharmaceuticals stated that the newly approved formulation is expected to expand its injectable pain-management portfolio in the regulated generics segment.

What does the FDA approval for Alembic Pharmaceuticals’ Ketorolac Tromethamine injectable mean for the US market?

Ketorolac Tromethamine is a widely used parenteral NSAID in hospital and surgical settings, valued for its opioid-sparing analgesic effect. The US FDA’s final approval signals that Alembic Pharmaceuticals has met the agency’s standards for bioequivalence, manufacturing quality, and labeling requirements relative to the reference listed drug, Toradol Injection by Roche.

According to market data from IQVIA for the 12-month period ending June 2022, the US market for Ketorolac Tromethamine Injection USP was estimated at approximately USD 59 million. While modest in size compared to other generic segments, the category remains important in hospital formulary procurement due to consistent demand in post-operative and acute care environments.

Industry analysts tracking the hospital injectable space note that Ketorolac Tromethamine maintains stable market penetration, particularly where opioid-reduction protocols are in place. This dynamic positions approved generics to benefit from predictable, contract-driven purchasing cycles.

How does this approval fit into Alembic Pharmaceuticals’ sterile injectables strategy?

This is the second injectable product approval from Alembic Pharmaceuticals’ general sterile manufacturing facility F-3, which underwent an FDA inspection in August 2022. The F-3 plant is part of the company’s broader investment in sterile dosage forms, an area it has been expanding to complement its established oral solid dosage portfolio.

The recent approval for Ketorolac Tromethamine follows closely on the heels of Alembic Pharmaceuticals securing FDA clearance for its Mesalamine Extended-Release Capsules USP, 0.375 g, earlier in the same week. Together, these approvals reflect a steady pipeline execution across multiple therapeutic categories.

Alembic Pharmaceuticals has been increasingly targeting complex generics and injectables for the US market, aligning with a strategy adopted by several leading Indian pharmaceutical exporters. The goal is to move beyond high-competition, low-margin oral solids into dosage forms that require greater technical capability and have fewer generic competitors.

What is Ketorolac Tromethamine and how is it used in clinical settings?

Ketorolac Tromethamine belongs to the NSAID class of drugs and exerts its analgesic effect by inhibiting cyclooxygenase (COX) enzymes, thereby reducing prostaglandin synthesis. It is typically used for short-term treatment of moderate to severe acute pain that requires analgesia at the opioid level, often in post-surgical scenarios.

The US FDA-approved labeling limits the duration of therapy to a maximum of five days in adults to minimize the risk of adverse events such as gastrointestinal bleeding, renal impairment, and cardiovascular complications. The injectable formulation allows for rapid onset of pain relief, making it a preferred choice in emergency departments, post-anesthesia care units, and inpatient settings.

As a non-opioid analgesic, Ketorolac Tromethamine is also valued in multimodal pain-management regimens, helping reduce reliance on narcotics and their associated risks.

Why is the US hospital generics market a focus area for Indian pharmaceutical exporters?

The US hospital generics segment is characterized by high regulatory compliance requirements, strict supply reliability standards, and the need for sterile manufacturing expertise. For Indian pharmaceutical manufacturers like Alembic Pharmaceuticals, success in this space represents not just revenue potential but also credibility in regulated markets.

Sterile injectables, unlike many oral generic products, require specialized manufacturing facilities, advanced quality control systems, and experienced technical teams. These barriers to entry tend to limit the number of competitors, supporting more sustainable pricing and longer product life cycles.

Furthermore, many hospital-administered drugs are purchased through group purchasing organizations (GPOs) that seek long-term supply contracts. This creates an environment where approved suppliers with proven compliance records can maintain stable order volumes.

What does the approval indicate about Alembic Pharmaceuticals’ regulatory compliance?

The F-3 sterile facility’s ability to secure multiple FDA approvals within a short span suggests operational readiness and compliance alignment with US current Good Manufacturing Practice (cGMP) standards. The August 2022 inspection by the US FDA was a key milestone, and subsequent approvals point to a positive regulatory outcome.

For Alembic Pharmaceuticals, such approvals enhance its track record with international regulators, which can influence its prospects in other regulated markets beyond the US, including Europe, Canada, and Australia.

What is the outlook for Alembic Pharmaceuticals following this approval?

With Ketorolac Tromethamine now part of its US injectables portfolio, Alembic Pharmaceuticals is positioned to compete for supply contracts in a stable therapeutic category. The near-term impact will depend on its ability to scale production, secure distribution agreements, and integrate the product into existing hospital sales channels.

Given the competitive but steady nature of the hospital NSAID segment, market share growth will likely rely on pricing strategies, supply reliability, and relationships with GPOs and hospital systems.

This approval also supports Alembic Pharmaceuticals’ broader narrative of diversifying its US product portfolio. The company has historically derived a significant portion of its US revenue from oral solids, but recent moves into injectables and complex generics could shift the revenue mix over the next few years.